跳至主要内容
临床试验/NCT05893069
NCT05893069暂停4 期

Ability of Oral Oxandrolone to Aid in Rehabilitation and Outcomes of Multiligament Knee Reconstructions: A Double-Blind, Randomized Controlled Trial

George F. Hatch1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
暂停
发起方
入组人数
60
试验地点
1
主要终点
body fat percentage

研究概览

简要总结

This study is about healing after a rmultiligament knee reconstruction procedure. We hope to learn if a biologic medication: Oxandrolone, a synthetic derivative of the human hormone Testosterone (the principal male sex hormone and an anabolic steroid), given for 12 weeks is effective in aiding in the healing process and restoring muscle mass.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Randomized

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with MRI proven multiligament knee injury scheduled to undergo multiligament knee reconstruction

排除标准

  • Patients with prior ipsilateral knee surgery
  • Untreated diabetes mellitus
  • Pituitary tumor
  • Rheumatoid Arthritis
  • Uncontrolled hypertension
  • Congestive Heart Failure
  • Myocardial Infarction within the past 6 months
  • End-stage renal disease
  • Liver enzymes two times the normal value
  • DVT within the past 6 months
  • Disorder of the coagulation system
  • Currently taking anticoagulation
  • Prior or current use of anabolic steroids
  • Chromosomal disorders
  • Prostate cancer
  • Breast cancer
  • Hypercalcemia
  • Patients with COPD not responsive to bronchodilators
  • Patients with known liver disease
  • Patients at risk for liver tumors
  • Severe hyperlipidemia
  • Patients taking medications that interfere with testosterone production or function, including but not limited to 5α-reductase inhibitors, acetaminophen (Tylenol, others), cholesterol lowering

研究组 & 干预措施

Treatment group

Experimental

Oxandrolone

干预措施: Oxandrolone (Drug)

Placebo Group

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

body fat percentage

时间窗: Change from baseline at 52 weeksf

measured by bioelectrical impedance analysis

lean body mass

时间窗: Change from baseline at 52 weeks

measured by bioelectrical impedance analysis

次要结局

未报告次要终点

研究者

发起方
George F. Hatch
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

George F. Hatch

Associate Professor

University of Southern California

研究点 (1)

Loading locations...

相似试验